Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioCryst Pharmaceuticals Inc BCRX

Healthcare Biotechnology
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of... see more

Recent & Breaking News (NDAQ:BCRX)

BioCryst to Present at Upcoming Investor Conferences

GlobeNewswire June 1, 2022

BioCryst to Present at Upcoming Investor Conferences

GlobeNewswire May 6, 2022

BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones

GlobeNewswire May 5, 2022

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 4, 2022

European Medicines Agency Grants PRIME Designation to BioCryst's ALK-2 Inhibitor, BCX9250, for Treatment of Fibrodysplasia Ossificans Progressiva

GlobeNewswire April 27, 2022

BioCryst to Report First Quarter 2022 Financial Results on May 5

GlobeNewswire April 21, 2022

BioCryst to Present at Upcoming Investor Conference

GlobeNewswire April 11, 2022

BioCryst Pauses Enrollment in BCX9930 Clinical Trials

GlobeNewswire April 8, 2022

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 5, 2022

BioCryst to Present at Upcoming Investor Conferences

GlobeNewswire March 3, 2022

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 2, 2022

BioCryst Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among HAE Patients Following Long-Term Treatment with ORLADEYO® (berotralstat)

GlobeNewswire February 24, 2022

BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key Milestones

GlobeNewswire February 23, 2022

BioCryst Begins Patient Enrollment in RENEW Proof-of-Concept Trial Evaluating BCX9930 for Patients with Renal Complement-mediated Diseases

GlobeNewswire February 22, 2022

BioCryst to Report Fourth Quarter 2021 Financial Results on February 23

GlobeNewswire February 9, 2022

BioCryst Appoints Machelle Sanders to Board of Directors

GlobeNewswire February 8, 2022

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 3, 2022

BioCryst to Present New ORLADEYO® (berotralstat) Data at 2022 American Academy of Allergy, Asthma & Immunology Annual Meeting

GlobeNewswire February 1, 2022

BioCryst Announces Preliminary Full Year 2021 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2022 ORLADEYO Net Revenue and Peak Sales Guidance

GlobeNewswire January 10, 2022

BioCryst Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH

GlobeNewswire January 7, 2022